Skip to main content
eScholarship
Open Access Publications from the University of California

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

  • Author(s): Hollestelle, A
  • Van Der Baan, FH
  • Berchuck, A
  • Johnatty, SE
  • Aben, KK
  • Agnarsson, BA
  • Aittomäki, K
  • Alducci, E
  • Andrulis, IL
  • Anton-Culver, H
  • Antonenkova, NN
  • Antoniou, AC
  • Apicella, C
  • Arndt, V
  • Arnold, N
  • Arun, BK
  • Arver, B
  • Ashworth, A
  • Baglietto, L
  • Balleine, R
  • Bandera, EV
  • Barrowdale, D
  • Bean, YT
  • Beckmann, L
  • Beckmann, MW
  • Benitez, J
  • Berger, A
  • Berger, R
  • Beuselinck, B
  • Bisogna, M
  • Bjorge, L
  • Blomqvist, C
  • Bogdanova, NV
  • Bojesen, A
  • Bojesen, SE
  • Bolla, MK
  • Bonanni, B
  • Brand, JS
  • Brauch, H
  • Brenner, H
  • Brinton, L
  • Brooks-Wilson, A
  • Bruinsma, F
  • Brunet, J
  • Brüning, T
  • Budzilowska, A
  • Bunker, CH
  • Burwinkel, B
  • Butzow, R
  • Buys, SS
  • Caligo, MA
  • Campbell, I
  • Carter, J
  • Chang-Claude, J
  • Chanock, SJ
  • Claes, KBM
  • Collée, JM
  • Cook, LS
  • Couch, FJ
  • Cox, A
  • Cramer, D
  • Cross, SS
  • Cunningham, JM
  • Cybulski, C
  • Czene, K
  • Damiola, F
  • Dansonka-Mieszkowska, A
  • Darabi, H
  • De La Hoya, M
  • Defazio, A
  • Dennis, J
  • Devilee, P
  • Dicks, EM
  • et al.

Published Web Location

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630206/
No data is associated with this publication.
Abstract

© 2015 Elsevier Inc. All rights reserved. Objective Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item